Development of Highly Selective Casein Kinase 1δ/1ε (CK1δ/ε) Inhibitors with Potent Antiproliferative Properties
10.1016/j.bmcl.2013.05.075 · doi-reference
Design and Synthesis of Novel Candidate CK1δ Proteolysis Targeting Chimeras (PROTACs)
10.3390/molecules30224452 · doi-reference
Development and Discovery of a Selective Degrader of Casein Kinases 1 δ/ε
10.1021/acs.jmedchem.4c02201 · doi-reference
Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1ε vs Casein Kinase 1δ
10.1021/acs.jmedchem.2c01180 · doi-reference
Structure-Based Optimization of Selective and Brain Penetrant CK1δ Inhibitors for the Treatment of Circadian Disruptions
10.1021/acsmedchemlett.3c00523 · doi-reference
Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity
10.1002/anie.202217532 · doi-reference
Casein Kinase 1 Enables Nucleus Accumbens Amphetamine-Induced Locomotion by Regulating AMPA Receptor Phosphorylation
10.1111/j.1471-4159.2011.07308.x · doi-reference
Inhibition of αENaC Expression and ENaC Activity Following Blockade of the Circadian Clock-Regulatory Kinases CK1δ/ε
10.1152/ajprenal.00678.2011 · doi-reference
IC261 Suppresses Progression of Hepatocellular Carcinoma in a Casein Kinase 1 δ/ε Independent Manner
10.1016/j.bbrc.2019.12.105 · doi-reference
Structural Basis for the Interaction between Casein Kinase 1 Delta and a Potent and Selective Inhibitor
10.1021/jm201387s · doi-reference
Pharmacological Targeting of Casein Kinase 1δ Suppresses Oncogenic NRAS-Driven Melanoma
10.1038/s41467-024-54140-1 · doi-reference
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-Selective, Noncovalent Tri-Complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
10.1021/acs.jmedchem.4c02314 · doi-reference
Design, Synthesis, and Evaluation of Novel p-(Methylthio)Styryl Substituted Quindoline Derivatives as Neuroblastoma RAS (NRAS) Repressors via Specific Stabilizing the RNA G-Quadruplex
10.1021/acs.jmedchem.8b00257 · doi-reference
Translational Suppression of KRAS and NRAS via RNA G-Quadruplex-Targeting Small Molecules for Colorectal Cancer Therapy
10.1021/acs.jmedchem.5c03088 · doi-reference
Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma
10.1021/acs.jmedchem.3c00094 · doi-reference
Design, Synthesis, and Evaluation of Novel Quindoline Derivatives with Fork-Shaped Side Chains as RNA G-Quadruplex Stabilizers for Repressing Oncogene NRAS Translation
10.1016/j.ejmech.2024.116406 · doi-reference
An RNA G-Quadruplex in the 5′ UTR of the NRAS Proto-Oncogene Modulates Translation
10.1038/nchembio864 · doi-reference
Small Molecule-Mediated Inhibition of Translation by Targeting a Native RNA G-Quadruplex
10.1039/c002418j · doi-reference
SHOC2 Phosphatase-Dependent RAF Dimerization Mediates Resistance to MEK Inhibition in RAS-Mutant Cancers
10.1038/s41467-019-10367-x · doi-reference
Targeting the SHOC2−RAS Interaction in RAS-Mutant Cancers
10.1038/s41586-025-08931-1 · doi-reference
Structural Basis for SHOC2 Modulation of RAS Signalling
10.1038/s41586-022-04838-3 · doi-reference
Combined Targeting of MEK and PI3K/mTOR Effector Pathways Is Necessary to Effectively Inhibit NRAS Mutant Melanoma in Vitro and in Vivo
10.1073/pnas.1216013110 · doi-reference
Enhanced BRAF Engagement by NRAS Mutants Capable of Promoting Melanoma Initiation
10.1038/s41467-022-30881-9 · doi-reference
Variation of Mutant Allele Frequency in NRAS Q61 Mutated Melanomas
10.1186/s12895-017-0061-x · doi-reference
Molecular Switch for Signal Transduction: Structural Differences Between Active and Inactive Forms of Protooncogenic Ras Proteins
10.1126/science.2406906 · doi-reference
Dabrafenib in BRAF-Mutated Metastatic Melanoma: A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial
10.1016/s0140-6736(12)60868-x · doi-reference
Vemurafenib in Patients with BRAF(V600) Mutated Metastatic Melanoma: An Open-Label, Multicentre, Safety Study
10.1016/s1470-2045(14)70051-8 · doi-reference
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
10.1200/jco.2011.41.2452 · doi-reference
The Arsenic Trioxide Paradox: A Targeted Therapy Triumph in APL versus a Metabolic Bottleneck Beyond
10.20517/element.2026.02 · doi-reference
Resistance Mechanisms in Melanoma to Immuneoncologic Therapy with Checkpoint Inhibitors
10.20517/cdr.2019.28 · doi-reference
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial
10.1001/jamaoncol.2025.5751 · doi-reference
Emerging Therapies in the Treatment of Advanced Melanoma
10.1016/j.cps.2021.06.008 · doi-reference
New Therapeutic Options for Advanced Non-Resectable Malignant Melanoma
10.1016/j.advms.2014.12.002 · doi-reference
Determinants of Resistance and Response to Melanoma Therapy
10.1038/s43018-024-00794-1 · doi-reference
